Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen, Sage face uphill battle with postpartum depression pill
07:39am, Monday, 07'th Aug 2023
The U.S. drug regulator's approval of Biogen and Sage Therapeutics' first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday.
FDA approves first-ever pill for postpartum depression in new mothers
07:40pm, Friday, 04'th Aug 2023
The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression.
US FDA approves Biogen-Sage Therapeutics pill for clinical depression
07:11pm, Friday, 04'th Aug 2023
The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill for two common forms of depression, paving the way for patients to get a faster-acting therapy to treat
3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now
03:17pm, Wednesday, 02'nd Aug 2023
Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical devi
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
02:59pm, Tuesday, 01'st Aug 2023
The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
05:45am, Tuesday, 01'st Aug 2023
Biogen's revenue has been on the decline as the company relies on older products that are losing exclusivity. The acquisition of Reata Pharmaceuticals offers Biogen a new product that could help drive
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
07:45am, Monday, 31'st Jul 2023
Biogen and Eli Lilly are two major competitors in the field of Alzheimer's disease. Eli Lilly's medicine appears to slow the rate of cognitive decline more than Biogen's.
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
09:08am, Saturday, 29'th Jul 2023
As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new
Biogen to buy rare-disease drugmaker Reata in $7.3B deal
05:26pm, Friday, 28'th Jul 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
S&P 500 Gains and Losses Today: Stocks Jump as Inflation Cools
05:10pm, Friday, 28'th Jul 2023
U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.
Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs
04:40pm, Friday, 28'th Jul 2023
Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.
Biogen's Alzheimer's drug is the biggest growth catalyst for the stock, says Jefferies' Yee
03:27pm, Friday, 28'th Jul 2023
Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for Biogen stock, and more.
Why Biogen Agreed to Acquire Reata for $7.3 Billion
02:45pm, Friday, 28'th Jul 2023
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets.
Biogen to acquire Reata Pharmaceuticals for $7.3B
10:06am, Friday, 28'th Jul 2023
Biogen Inc (NASDAQ:BIIB) said it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion in cash as it bulks up its neuromuscular and rare disease portfolio. Shares of Reata shot up 52% to
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
09:45am, Friday, 28'th Jul 2023
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
